KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Taxes (2016 - 2025)

Historic Change in Taxes for Emergent BioSolutions (EBS) over the last 14 years, with Q3 2025 value amounting to $6.2 million.

  • Emergent BioSolutions' Change in Taxes fell 4095.24% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 9064.75%. This contributed to the annual value of $23.3 million for FY2024, which is 24382.72% up from last year.
  • Per Emergent BioSolutions' latest filing, its Change in Taxes stood at $6.2 million for Q3 2025, which was down 4095.24% from $6.8 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Change in Taxes high stood at $79.7 million for Q4 2022, and its period low was -$40.9 million during Q2 2022.
  • For the 4-year period, Emergent BioSolutions' Change in Taxes averaged around $2.9 million, with its median value being -$1.0 million (2023).
  • Data for Emergent BioSolutions' Change in Taxes shows a peak YoY increase of 33454.55% (in 2023) and a maximum YoY decrease of 28478.26% (in 2023) over the last 5 years.
  • Emergent BioSolutions' Change in Taxes (Quarter) stood at $79.7 million in 2022, then plummeted by 115.93% to -$12.7 million in 2023, then skyrocketed by 74.02% to -$3.3 million in 2024, then skyrocketed by 287.88% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $6.8 million for Q2 2025, and -$8.4 million during Q1 2025.